Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This study is a single-center, randomized, placebo-controlled, double-blind, single ascending
dose escalation study to determine the safety, tolerability, and PK profile of oral
administration of HPN-07 in single doses to approximately 32 healthy male and female subjects
between 18 and 55 years of age.
Subjects will receive single oral doses of the study drug. The primary endpoint of this trial
is to establish the safety and tolerability of HPN-07 and HPN-07 plus N-acetylcysteine (NAC).